City Of Portsmouth: Evusheld Treatment

Portsmouth NH

17 December, 2021

10:14 AM

Description

Press release from the City of Portsmouth: December 16, 2021 Tixagevimab and cilgavimab , the two long-acting monoclonal antibodies in Evusheld, target the spike protein of SARS-CoV-2, blocking the viruses' attachment and entry into human cells. This press release was produced by the City of Portsmouth. The views expressed here are the author's own.